Skip to main content

Advertisement

Table 1 Characteristics of donor groups enrolled into the study

From: Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study

Group/parameter Healthy control Cancer patients (all cases) Patients with locally advanced cancer Patients with metastatic cancer
No spread Spread
Number (n) 50 53 19 16 18
Sex (M/F) 30/20 37/16 12/7 13/3 12/6
Age (years) 28–60 (median 50) 34–74 (median 59) 36–70 (median 59) 34–73 (median 58) 35–74 (median 60)
Tumor location
 Upper third 15 (28 %) 3 (16 %) 6 (37 %) 6 (33 %)
 Middle third 31 (59 %) 13 (68 %) 9 (57 %) 9 (50 %)
 Lower third 7 (13 %) 3 (16 %) 1 (6 %) 3 (17 %)
Histological grade
 G1–G2 16 (30 %) 10 (53 %) 3 (19 %) 3 (17 %)
 G3 29 (55 %) 8 (42 %) 11 (69 %) 10 (56 %)
 Not specified 8 (15 %) 1 (5 %) 2 (12 %) 5 (27 %)
Primary tumor
 cT1–T3 50 (94 %) 19 (100 %) 16 (100 %) 15 (83 %)
 cT4 3 (6 %) 0 (0 %) 0 (0 %) 3 (17 %)
Lymph node
 cN0 20 (38 %) 13 (68 %) 5 (31 %) 2 (11 %)
 cN1–N3 33 (62 %) 6 (32 %) 11 (69 %) 16 (89 %)
Metastasis (initial)
 cM0 35 (66 %) 19 (100 %) 16 (100 %) 0 (0 %)
 cM1 18 (34 %) 0 (0 %) 0 (0 %) 18 (100 %)
  1. Group of patients with locally advanced cancer at time of diagnosis were further split into subgroup where either no spread (control) or consecutive cancer dissemination/spread (distant metastasis) was detected